Mega Genomics

Mega Genomics P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics (6667.HK) as of Oct 16, 2026 is -69.06. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 20.43 — a change of -437.97% (lower).

P/FCF

-69.06

YoY

-437.97%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics is 2025 -69.06 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics was 2024 20.43 . It decreases by -437.97% lower compared to the previous year.

The Mega Genomics P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
36.80 CNY
Jan 1, 2020
13.20 CNY
Jan 1, 2021
43.95 CNY
Jan 1, 2022
-95.21 CNY
Jan 1, 2023
10.53 CNY
Jan 1, 2024
20.43 CNY
Jan 1, 2025
-69.06 CNY
The Mega Genomics P/FCF history
YEARP/FCFYoY
-69.06-437.97%
20.43+94.01%
10.53-111.06%
-95.21-316.60%
43.95+232.97%
13.20-64.13%
36.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd, listed on the Hong Kong Stock Exchange under ticker 6667.HK with ISIN KYG5960G1047, is a health care company headquartered in Beijing, China. The company, which went public on June 22, 2022, employs 267 full-time staff. Mega Genomics operates as a genetic testing platform, offering consumer genetic testing and cancer screening services. Its business is structured into three segments. The Consumer Genetic Testing Services segment provides tests related to nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing, and infectious disease testing. The Cancer Screening Services segment offers specific tests including the Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test, and the ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment delivers genetic research and analysis services to third-party research institutions. The company's website is https://www.megagenomics.cn/. Mega Genomics focuses on providing genetic testing solutions for both consumer and clinical applications, with an emphasis on cancer-related screening and personalized health assessments. The company's operations are based in Beijing, reflecting its position within China's growing health care sector. As a publicly traded entity, Mega Genomics is subject to the regulatory requirements of the Hong Kong Stock Exchange. Mega Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mega Genomics stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics is -69.06 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics changed from 20.43 to -69.06, representing a -437.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Mega Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Mega Genomics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Mega Genomics